Page 31 - Demo

SECTION I: MOLECULAR GENETIC ENGINEERING AND BIOCHEMICAL TECHNOLOGY 35ClpC1 functions in protein breakdown with the ClpP1P2 protease complex. Ecumicin markedly enhanced the ATPase activity of wild-type (WT) ClpC1 but prevented activation of proteolysis by ClpC1. Less stimulation was observed with ClpC1 from ecumicinresistant mutants. Thus, ClpC1 is a valid drug target against M. tuberculosis, and ecumicin may serve as a lead compound for antiTB drug development. Funding: This work was supported in part by a grant to J.-W. Suh from the Next-Generation BioGreen 21 Program (no. PJ009643), Rural Development Administration, Republic of Korea.. Acknowledgments: This study was collaborated with the researchers in Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago. Conflicts of Interest: The authors declare no conflict of interest.REFERENCES1. Treatment Outcomes among Patients with MultidrugResistant Tuberculosis: Systematic Review and Meta-Analysis - ScienceDirect Available online: https://www.sciencedirect.com/science/article/pii/S1473309909700416?via%3Dihub (accessed on 7 December 2024).2. Manikkam, R.; Venugopal, G.; Subramaniam, B.; Ramasamy, B.; Kumar, V. Bioactive Potential of Actinomycetes from Less Explored Ecosystems against Mycobacterium Tuberculosis and Other Nonmycobacterial Pathogens. Int Sch Res Notices2014, 2014, 812974, doi:10.1155/2014/812974.3. Selim, M.S.M.; Abdelhamid, S.A.; Mohamed, S.S. Secondary Metabolites and Biodiversity of Actinomycetes. J Genet Eng Biotechnol 2021, 19, 72, doi:10.1186/s43141-021-00156-9.